Low‑Dose Naltrexone for Fibromyalgia: What the New Research Really Means

If you live with fibromyalgia, you’ve probably heard people talk about low‑dose naltrexone (LDN). For years, it’s been one of those treatments that sits in the “maybe” category — not officially recommended, but often discussed in support groups, online forums, and even some clinics. Many people have hoped it might be a gentler, safer option for managing chronic pain.

A major new study presented at the EULAR 2026 Annual Meeting — one of the biggest rheumatology conferences in the world — has now given us the clearest answer so far. And while the results may feel disappointing, they also bring clarity, reassurance, and a better understanding of what fibromyalgia really is.

Let’s walk through what the study found, what it means, and why it’s not all bad news.

First, what exactly is naltrexone?

Naltrexone is a medication that’s been around for decades. At high doses (50 mg), it’s used to help people with opioid or alcohol dependence. At those doses, it works by blocking opioid receptors — the same receptors that painkillers like morphine act on.

But at very low doses (usually 1–6 mg), the drug seems to behave differently. Researchers believe that low‑dose naltrexone may:

• Calm down overactive immune cells in the brain (called microglia)
• Temporarily block opioid receptors in a way that causes the body to release more natural endorphins
• Influence pain signalling pathways

These ideas made LDN an exciting possibility for conditions like fibromyalgia, ME/CFS, and neuropathic pain. Small early studies suggested it might help. But those studies were tiny — often fewer than 20 people — and results were mixed.

That’s why this new trial matters so much.

What did the new EULAR 2026 study actually test?

This was the largest and most rigorous LDN trial in fibromyalgia so far. It lasted 12 months and included 96 women with fibromyalgia. They were randomly assigned to:

• 4.5 mg of LDN daily, or
• A placebo (a pill with no active medication)

Everyone in the study:

• Was in their 50s on average
• Had lived with fibromyalgia for around 8 years
• Had high rates of depression and other emotional symptoms (very common in fibromyalgia)

Researchers looked at:

• Pain levels
• Functioning
• Anxiety and depression
• Stress
• Cognitive symptoms (“fibro fog”)
• Overall wellbeing

They checked these at 3, 6, and 12 months.

The big finding: LDN did not work better than placebo

At the 3‑month mark — the main point the study was designed to measure — both groups had tiny improvements in pain:

• LDN group: pain improved by 0.33 points
• Placebo group: pain improved by 0.64 points

On an 11‑point scale, these changes are so small that they don’t make a meaningful difference in real life.

And importantly, placebo did slightly better.

Over the full 12 months, there were small ups and downs in symptoms, but again, no real difference between LDN and placebo.

The lead researcher, Dr Juan Luciano, summed it up simply: The results were “quite disappointing” and LDN “does not give a meaningful reduction in pain or distress.”

Why this still matters — and why it’s not a failure

Another expert at the conference, Dr Jasminka Milas‑Ahic, made an important point: Even though the results were negative, the study was very well designed and gives clinicians and patients valuable clarity.

Negative studies are just as important as positive ones. They help us avoid spending time, money, and emotional energy on treatments that don’t actually help.

And this isn’t the only study pointing in this direction. A major trial published in The Lancet Rheumatology in 2024 also found that LDN did not outperform placebo for fibromyalgia pain.

Together, these two studies give us the strongest evidence so far: LDN is not an effective pain treatment for fibromyalgia.

But here’s something fascinating: expectations mattered

Even though LDN didn’t work better than placebo, the researchers noticed something interesting:

People who believed they were taking LDN reported improvements in some symptoms.

This doesn’t mean the improvements were “all in their head.” In chronic pain conditions like fibromyalgia, the brain plays a huge role in how pain is processed. Expectation, hope, and the feeling of being cared for can genuinely change how the nervous system behaves.

This is part of what we call the placebo response — and it’s powerful.

It also helps explain why earlier, smaller studies seemed more positive. When people strongly believe a treatment will help, the brain often responds in ways that reduce pain, stress, and tension.

This is not fake. It’s biology.

So what does this mean for people living with fibromyalgia?

1. LDN is not a reliable pain treatment

Based on the best evidence we have, LDN does not reduce pain, distress, or disability in fibromyalgia.

2. It may still have small benefits for some symptoms

The Lancet trial suggested LDN might help with memory problems, but this needs more research.

3. It is generally safe

Side effects were similar to placebo in both major trials.

4. The placebo effect is real and meaningful

Understanding this helps us appreciate how powerful the brain is in shaping pain — and how important hope, support, and expectation are in treatment.

5. Fibromyalgia is complex — and no single pill is likely to fix it

This is the hardest truth, but also the most freeing one.

Fibromyalgia involves:

• Central sensitisation
• Altered pain processing
• Emotional and cognitive factors
• Sleep disruption
• Stress sensitivity

Because of this, the most effective approaches tend to be multidisciplinary, including:

• Pain education
• Psychological therapies (like ACT or CBT)
• Pacing and graded activity
• Sleep strategies
• Lifestyle changes
• Supportive relationships
• Mind‑body approaches

Medication can help some symptoms, but it’s rarely the main solution.